Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ALT
ALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALT News
Altimmune to Report Q1 2026 Financial Results on May 13
4d ago
Newsfilter
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
Apr 28 2026
stocktwits
Lululemon's New CEO Announcement Triggers Stock Decline
Apr 24 2026
stocktwits
Altimmune Prices $225 Million Public Offering at 13.5% Discount
Apr 23 2026
stocktwits
Altimmune Prices Oversubscribed $225 Million Public Offering
Apr 23 2026
NASDAQ.COM
Altimmune Prices Oversubscribed Public Offering Raising $225 Million
Apr 23 2026
seekingalpha
Altimmune Prices $225 Million Public Offering for Pemvidutide Development
Apr 23 2026
Newsfilter
Concentrix and Altimmune Executives Increase Stock Holdings
Apr 10 2026
NASDAQ.COM
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
Mar 27 2026
stocktwits
AvaíBio Initiates α-Klotho Cell Bank Creation
Mar 24 2026
PRnewswire
AvaíBio Initiates Master Cell Bank for α-Klotho Production
Mar 24 2026
Newsfilter
Novo Nordisk's High-Dose Wegovy Approved by FDA
Mar 19 2026
CNBC
Truist Initiates Buy Rating on Altimmune, Highlights Pemvidutide's Potential
Mar 18 2026
seekingalpha
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
Mar 05 2026
seekingalpha
Altimmune's Financial Status and Trial Progress
Mar 05 2026
stocktwits
Altimmune Announces Late-Stage Trial Plans for Pemvidutide
Mar 05 2026
seekingalpha
Show More News
